AzurRx BioPharma (NASDAQ:AZRX) has been given a $6.00 price target by equities researchers at Oppenheimer in a report issued on Thursday. The firm presently has a “buy” rating on the stock. Oppenheimer’s price objective would suggest a potential upside of 158.62% from the stock’s previous close.
AZRX has been the topic of a number of other reports. CIBC began coverage on shares of AzurRx BioPharma in a report on Wednesday, October 17th. They issued an “outperform” rating and a $6.00 target price on the stock. HC Wainwright restated a “buy” rating and issued a $6.00 target price on shares of AzurRx BioPharma in a report on Friday, August 17th.
AzurRx BioPharma stock opened at $2.32 on Thursday. AzurRx BioPharma has a twelve month low of $2.10 and a twelve month high of $4.08.
Several institutional investors have recently bought and sold shares of the company. 683 Capital Management LLC bought a new position in AzurRx BioPharma during the 2nd quarter valued at about $1,284,000. Gilder Gagnon Howe & Co. LLC bought a new position in AzurRx BioPharma during the 2nd quarter valued at about $1,782,000. Opaleye Management Inc. bought a new position in AzurRx BioPharma during the 2nd quarter valued at about $417,000. Finally, Ardsley Advisory Partners grew its holdings in AzurRx BioPharma by 66.3% during the 2nd quarter. Ardsley Advisory Partners now owns 137,197 shares of the company’s stock valued at $440,000 after purchasing an additional 54,697 shares during the last quarter. Hedge funds and other institutional investors own 18.61% of the company’s stock.
AzurRx BioPharma Company Profile
AzurRx BioPharma, Inc researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea.
See Also: Hedge Funds – Risk or Reward?
Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.